Royalty Report: Drugs, Cancer, Therapeutic – Collection: 299246

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 299246

License Grant
English Licensor agrees to grant and hereby grants to the Licensee an exclusive worldwide royalty-bearing revocable right and licence, with rights to sublicence, under the patent rights to use Platinum Complexes, the Licensors information and the Licensors ongoing information to make, have made, use, offer to sell, and have sold products for use within the field.
License Property
Platinum complex JM 216 is used in the treatment of tumor cells.

Products are the formulation in the research and development using JM 216 and other Platinum Complexes within the field.

Patent Rights shall mean the Patents arising out of or resulting from each such Patent, and any other U.S. and foreign Patents having claims covering or directed to the Licensed Compound or the Know-How.

Field of Use
Satraplatin is an orally-administered platinum derivative.  Platinum derivatives are one of the most active classesof cytotoxic anti-cancer agents and are currently used to treat a wide rangeof cancers. A large phase 2 program has shown efficacy in the treatment of hormone-resistantprostate cancer as well as several other tumor types.

IPSCIO Record ID: 514

License Grant
Licensor agrees to grant and hereby grants to the Licensee an exclusive worldwide royalty-bearing revocable right and license under the Patent Rights, with rights to sub-license, to use the Platinum Complexes, the Licensor’s Information and the Licensor’s Ongoing Information to make, have made, use, offer to sell, and have sold Products for use within the Field.
License Property
The Licensor has developed and is the beneficial owner of a substantial body of valuable technical information relating to the use of the platinum complex JM216 in the treatment of tumor cells, toxicity data and other valuable information and is the beneficial owner of the Patent Rights relating thereto as defined hereinafter.

JM216 the platinum complex bis(acetato)amminedichloro(cyclohexyl-amine)platinum(IV).

Field of Use
Field the use of the Products for the purpose of treating cancer in humans and the sale of the Products for such purpose.

IPSCIO Record ID: 291191

License Grant
University hereby grants to Licensee a worldwide sole and exclusive license under the Patent Rights and Know-How to make, have made, use, import, export, offer for sale and sell the Licensed Products.
License Property
Patent Rights shall mean the interest of University in

(a)
the United States and foreign patents and/or patent applications listed;

(b)
United States and foreign patents issued from the applications listed and from divisionals, continuations and continuations-in-part of these applications;

(c)
claims of U.S. and foreign continuation-in-part applications, and of the resulting patents, which are directed to subject matter specifically described in the U.S. and foreign applications listed; and

(d)
claims of all foreign patent applications, and of the resulting patents, which are directed to subject matter specifically described in the United States patents and/or patent applications described in (a), (b) or (c) above.

6,087,350 – Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
6,559,139 – Combination chemotherapy

Licensed Product shall mean Vitamin D and one or more cytotoxic agents administered or otherwise used or offered for use in a manner which would, but for the license granted herein, infringe one or more of the Patent Rights.

Vitamin D shall mean cholecalciferol, as well as all derivatives and analogs thereof or thereto.

Field of Use
One of the issued U.S. patents claims a method of killing cells such as cancer cells with any vitamin D derivative together with paclitaxel or cyclophosphamide. The second issued patent claims a method of killing neoplastic cells with any vitamin D derivative together with  carboplatin, cisplatin, paclitaxel or Taxotere.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.